"Muscular dystrophy meets protein biochemistry, the mother of invention
The mechanism whereby a contractile multinucleated skeletal muscle fiber is linked to the basement membrane (BM) that ensheaths it represents a paradigm for our understanding of BM assembly and interactions between the cell and extracellular matrix in the context of human pathobiology. Multiple matrix proteins, cell-surface receptors, transmembrane accessory proteins, cytoskeletal linker proteins, and glycosylating enzymes are required for the establishment and maintenance of the large, integrated complex that tightly links the myofiber cytoskeleton to the sarcolemma (plasma membrane) and the sarcolemma to the skeletal muscle BM (1) . Genetic defects that alter the expression, structure, or function of these proteins cause a devastating class of diseases, the muscular dystrophies.
Muscular dystrophies are characterized by the progressive degeneration and weakness of skeletal muscle that includes muscle fiber necrosis, regeneration, and fibrosis (2) . The severity and rate of progression of muscular dystrophy can vary dramatically, from congenital forms to the more common delayed-onset form known as Duchenne muscular dystrophy (3) . From a cell biological perspective, muscular dystrophies with a genetic basis can be divided into types that correspond roughly to the site of the protein or protein complex that is affected by mutation. Mutations that affect the muscle BM cause congenital muscular dystrophy; those that affect the cytoskeletal protein dystrophin cause Duchenne and Becker muscular dystrophy; and those that affect transmembrane proteins called sarcoglycans cause limb-girdle muscular dystrophy (3). Interestingly, mutations that impact the enzymes responsible for glycosylation of dystroglycan cause the dystroglycanopathies, which manifest as muscular dystrophies with variable degrees of severity and timing of onset, as well as variable CNS and eye defects (4) . Dystroglycan serves as the functional centerpiece of the dystrophin-glycoprotein complex that links the cytoskeleton to the BM and, therefore, plays a crucial role in maintaining skeletal muscle health (5).
Laminin and the basement membrane
Like all BMs, the skeletal muscle fiber BM contains specific isoforms from four major matrix protein families: laminins, type IV collagens, nidogens, and heparan sulfate proteoglycans. Laminins are large heterotrimeric glycoproteins composed of one α, one β, and one γ chain (6) . The major laminin isoform of skeletal muscle BM is laminin α2β1γ1 (Lm211; Figure 1 , left), while a structurally and functionally different isoform, laminin α5β2γ1, is found at the neuromuscular junction (7). Lm211 is a cruciform macromolecule that can selfpolymerize in vitro to form a network via the formation of intermolecular ternary complexes involving the laminin N-terminal (LN) domain of each of the three chains (8) . The unique C-terminus of the α2 chain, called the laminin globular (LG) domain, binds to receptors on the surface of the myofiber, including α-dystroglycan and integrin α7β1 (1). The binding of laminin to its receptors as muscle forms is thought to have a dual purpose: a) initiation of BM formation by concentrating the laminin at the cell surface above a critical concentration that promotes polymerization; and b) sending a signal to the cell (9) . Upon maturation, laminin binding to its receptors links the muscle fiber to the BM, into which the laminin has become deeply integrated via direct and indirect interactions with nidogen, collagen IV, and proteoglycans.
Mutations in the laminin α2-encoding gene (LAMA2) cause congenital muscular dystrophy. Mutations that prevent production of the protein typically (though not always) cause more severe disease than do missense mutations, internal deletions, or mutations that reduce Lm211 protein levels (1) (Figure 1, middle) . The existence of several naturally occurring and engineered mouse models with Lama2 mutations with features of human congenital muscular dystrophy have been instrumental for investigating pathogenic mechanisms and potential treatments for both severe and milder forms of the disease (10).
Biochemistry and protein therapy
The Muscular dystrophies result from a defect in the linkage between the muscle fiber cytoskeleton and the basement membrane (BM). Congenital muscular dystrophy type MDC1A is caused by mutations in laminin α2 that either reduce its expression or impair its ability to polymerize within the muscle fiber BM. Defects in this BM lead to muscle fiber damage from the force of contraction. In this issue of the JCI, McKee and colleagues use a laminin polymerization-competent, designer chimeric BM protein in vivo to restore function of a polymerization-defective laminin, leading to normalized muscle structure and strength in a mouse model of MDC1A. Delivery of such a protein to patients could ameliorate many aspects of their disease.
nin network, albeit an aberrant network, to dystroglycan, which is likely the major mechanism of disease attenuation (14, 15) .
Patients who harbor mutations that only affect the LMα2 LN domain have mild phenotypes compared with those with mutations that result in total loss of LMα2 (16) , similar to missense mutations in the LMβ2 LN domain that affect the kidney glomerular BM of Pierson syndrome spectrum patients (17 /dy 2J mice. The αLNNd protein is composed of the LMα1 LN and LEa1-4 domains fused to the G2-G3 portions of nidogen, thereby replacing the nidogen G1 domain and short segment that connects G1 to the G2-G3 segment with the LMα1 N-terminus. The nidogen portion binds to LMγ1 LE3b via the G3 domain and to the collagen type IV network via the G2 domain, thereby preserving the laminin-collagen linkage. Biochemical studies and naturally existing laminin heterotrimer combinations (Lm111, Lm211) prove that both LMα1 and LMα2 LN domains facilitate polymerization through interactions with LMβ1 and LMγ1 LN domains. Additionally, both overexpression and exogenous provision of Lm111 can ameliorate muscular dystrophy in Lama2-mutant mice (18, 19) . Thus, the LMα1 LN domain of αLNNd readily substitutes for the missing LMα2 LN domain both in vivo and in vitro (11 3K mice). These mice and patients who lack LMα2 exhibit increased LMα4-and LMα5-containing trimers, but decreased α-dystroglycan expression. Although these laminins have poor musclespecific receptor binding, and LMα4 lacks the LN domain required for polymerization, Ruegg and colleagues hypothesized that a mini-agrin protein containing only the laminin-and dystroglycan-binding domains might both stabilize the laminin network and restore dystroglycan levels. Collectively, dy 3K/ dy 3K and dy w /dy w mice expressing mini-agrin in skeletal muscle via a transgene exhibited a marked increase in muscle function and lifespan and improved BM morphology, with increased incorporation of the polymerization-capable LMα5. In this scenario, mini-agrin links the lamied the intermolecular interactions among BM proteins and their cognate receptors that have been deciphered through decades of basic science research. In addition to laminin-receptor interactions, laminins are secondarily and indirectly linked to cellsurface receptors by the heparan sulfate proteoglycan agrin, which binds to the LMγ1 coiled-coil region via its N-terminal agrin domain as well as to dystroglycan and integrins via its C-terminal LG-like domains (12) . Furthermore, the laminin network is linked to the type IV collagen network by nidogen, which binds to the short arm LE3b segment of LMγ1 via nidogen's G3 domain and to a region in collagen IV near the Cterminal noncollagenous 1 (NC1) domain via nidogen's G2 domain (13) .
Previously, research teams led by Ruegg tested a molecular therapy in severe forms of congenital muscular dystrophy, in which able delivery systems and pharmaceutical strategies (1), hold promise as future therapeutics for congenital muscular dystrophy. Importantly, the small sizes of αLNNd (157 kDa) and mini-agrin (106 kDa) relative to the affected 341-kDa LMα2 chain and the approximately 750-kDa Lm211 trimer, together with the fact that αLNNd and mini-agrin function as monomers, make them well suited for therapeutic intervention, whether delivered as naked or virally encoded proteins.
